| Document |
Document Title |
|
WO/2023/281933A1 |
Provided is a reaction method that includes, in a gas-liquid reaction performed using a solid catalyst, alternately allowing a gaseous raw material 3 that includes a first raw material and a liquid raw material 5 that includes a second r...
|
|
WO/2023/281476A1 |
The present disclosure provides mimic molecules that are capable of specifically targeting a FAM19A5 protein, and thereby, inhibiting, reducing, and/or dissociating the interaction between members of the LRRC4 protein family and the FAM1...
|
|
WO/2022/269134A1 |
The present invention relates to an improved process for the preparation of 4H-pyranone structured CYP11A1 inhibitors such as 5-((1-(methylsulfonyl)-piperidin-4-yl)methoxy)-2-((5-(triflu
oromethyl)isoindolin-2-yl)methyl)-4H-pyran-4-one (...
|
|
WO/2022/264167A1 |
The invention disclosed herein relates to synergistic bioactive compositions for inhibiting vascular calcification. Particularly, the present invention relates to exogenous blend of magnesium 2-acetylamino ethane sulfonic acid and 2-meth...
|
|
WO/2022/261030A1 |
The present disclosure relates to compounds and methods of modulating target nucleic acids that contain single nucleotide polymorphisms such as KRAS codon 12 mutations. Compounds disclosed herein can preferentially bind a sequence of nuc...
|
|
WO/2022/253077A1 |
Provided are a pharmaceutical salt of fingolimod, a preparation method therefor, a pharmaceutical composition containing same and the use thereof. The pharmaceutical salt of fingolimod is a salt formed from a fingolimod free base and an ...
|
|
WO/2022/247801A1 |
Provided are an ionizable lipid compound with an adjacent cis-double bond structure, a preparation method therefor, and the use thereof in the delivery of an active therapeutic agent (e.g., a nucleic acid). The ionizable lipid compound c...
|
|
WO/2022/226812A1 |
A method for preparing L-terbutaline by using a chiral auxiliary group, which uses S-(-)-tert-butylsulfinamide as a raw material to sequentially react with tert-butylbromide and 3,5-dibenzyloxybromoacetophenone to obtain a compound 5; th...
|
|
WO/2022/225046A1 |
Provided is a composition which has excellent gel formation and thickening characteristics, excellent water retention and conductivity, an excellent stabilization effect in biological materials such as enzymes, in which active ingredient...
|
|
WO/2022/222913A1 |
The present invention provides a preparation method for L-nicotine. According to the method, L-nicotine having an optical purity of up to 99.7% can be obtained, and the total synthesis yield reaches 60-70%. In the whole preparation proce...
|
|
WO/2022/221942A1 |
Implantable product(s) and methods for predetermined release of one or more active pharmaceutical ingredients (APIs). More specifically, implantable, subcutaneous product(s) and methods for treating depression and other mental and/or moo...
|
|
WO/2022/222844A1 |
Disclosed in the present invention are an ionic liquid, a preparation method therefor, and an application thereof. The ionic liquid is prepared from vitamin A compounds and choline compounds, has the characteristics of good solubility an...
|
|
WO/2022/218295A1 |
The present disclosure relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, which can be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid.
|
|
WO/2022/220153A1 |
Provided is a thin film-forming feedstock, for use in atomic layer deposition, that contains a ruthenium compound represented by general formula (1) below. (In formula (1), R1, R2, R3, R4, R5, and R6 each independently represent a hydrog...
|
|
WO/2022/207426A1 |
A method of producing a compound formula (I), the method comprising: reacting a compound of formula (II) with a compound of formula (III), wherein, R3 is hydrogen or halogen; R1 and R2 are each independently C1-C6alkoxy, or R1 and R2 tog...
|
|
WO/2022/201519A1 |
A eutectic mixture contains a first component and a second component as main components. The first component is a quaternary ammonium salt, and the second component is an aminocarboxylic acid having a -COOH group and a -NH- group in the ...
|
|
WO/2022/204125A1 |
The present disclosure relates to crystalline polymorphs of N-(trans-4-hydroxycyclohexyl)-6-phenylhexanamide, and to pharmaceutical compositions that may be prepared from the polymorphs. The present disclosure also relates to uses of the...
|
|
WO/2022/200247A1 |
The present invention is related to the synthesis of 4-hydroxymethyl-2-oxazolidinone (serinol carbamate, SC), which can be subsequently hydrolyzed to 2-amino-1,3-propanediol (serinol), by reacting glycerol and urea: (I) In general, glyce...
|
|
WO/2022/193806A1 |
The present invention relates to a method for asymmetric catalytic synthesis of nicotine, specifically to a method for preparing nicotine by five-step reaction by using 3-bromopyridine as a starting material, specifically comprising: 1) ...
|
|
WO/2022/193368A1 |
The present invention belongs to the technical field of medicinal chemistry, and disclosed are a trans-amantadine derivative or a salt thereof, and a preparation method therefor, a composition thereof and the use thereof. Provided in the...
|
|
WO/2022/193369A1 |
The present invention relates to the technical field of pharmaceutical chemistry. Disclosed is a use of a trans amantadine derivative having a structure as represented by formula I or a pharmaceutically acceptable salt thereof in the pre...
|
|
WO/2022/183281A1 |
Among other things, in general, compositions and methods of treatment for muscular dystrophy and other diseases are disclosed. A method of treatment of a subject is disclosed, in which fatty acid utilization is improved. The method inclu...
|
|
WO/2022/181381A1 |
The present invention provides: a novel organic ammonium salt which has excellent freezing point lowering function; and a composition which is capable of forming this salt. An organic ammonium salt according to the present invention co...
|
|
WO/2022/172292A1 |
The present invention relates to a process for preparation of Abediterol of the Formula (I) or its pharmaceutically acceptable salts, and intermediate compounds including the compound of the Formula (VII) by chiral sulfide mediated epoxi...
|
|
WO/2022/168085A1 |
The present invention provides lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellula...
|
|
WO/2022/158993A1 |
The present invention relates to a method for the production of d-erythro-sphingosine and analogs thereof, wherein the method comprises a step of condensing a compound of formula (2): Formula (2), or a salt thereof, wherein R1 is hydroge...
|
|
WO/2022/148456A1 |
Pharmaceutical compositions comprising a chemotherapeutic agent based on a β-substituted β-amino acid derivative are disclosed. The pharmaceutical compositions include a β-substituted β-amino acid derivative and a cyclodextrin deriva...
|
|
WO/2022/140518A1 |
A composition comprising a non-cationic amine epoxide adduct is disclosed, along with methods of making the same. Use of a composition comprising a non-cationic amine epoxide adduct on textiles and paper, particularly woven textiles, tis...
|
|
WO/2022/134203A1 |
Disclosed is a novel method for preparing monoethanolamine, and the present invention belongs to the field of coal chemical engineering. The method of the present invention involves using methyl glycolate, which is an intermediate produc...
|
|
WO/2022/132364A1 |
The present disclosure generally relates to a friction modifier comprising the reaction product of an organic amine and glycidol and its use in a non-aqueous lubricant composition. There is also provided a method for reducing the frictio...
|
|
WO/2022/130403A1 |
The present invention relates to a new quaternary ammonium trifluoromethyl salts of formula (I), a process for the preparation thereof and its application in trifluoromethylation: (I) wherein, R1, R2, R3 and R4 are branched or linear C1-...
|
|
WO/2022/133362A1 |
Disclosed are facile methods of purifying a cannabis extract to produce highly purified, crystallized cannabinoid acids, and in particular cannabinoid acids such as THCA, and removing impurities from the same, by using polar aprotic solv...
|
|
WO/2022/129909A1 |
The present invention relates to a group of novel compounds, methods for their manufacture and the use of these compounds as research tools and as pharmaceuticals. The novel compounds are analogues of cannabidiol (CBD). CBD is a non-psyc...
|
|
WO/2022/122931A1 |
A process for the removal of an inorganic salt from a feed liquid comprising an inorganic salt and an organic compound comprising a hydroxy group and/or an amine group, comprising passing the feed liquid through an electrodialysis (ED) u...
|
|
WO/2022/121317A1 |
Disclosed is a 1,1'-biphenyl-2,6-diphenolic compound and the use thereof. The 1,1'-biphenyl-2,6-diphenolic compound is a new compound, and has good biological activity. By means of in vitro tumor cell activity experiments, it was found t...
|
|
WO/2022/113098A1 |
The present invention relates to an environment-friendly process for selective acylation of aminophenol. In particular, the present invention relates to an environment-friendly process for selective acylation of para-aminophenol to obtai...
|
|
WO/2022/099284A1 |
The present invention provides compositions comprising compounds having formulas (I), (II) or (III): and additionally provides methods for the use thereof in the treatment of various disorders including neurological disorders, cancer, di...
|
|
WO/2022/087248A1 |
Disclosed herein are polymers formed by the condensation of bis(hydroxycarbyl)- aminophenolic compounds with aldehydes. The condensation polymers include one or more repeat units having bis(hydroxycarbyl)amino functionality. The hydroxyl...
|
|
WO/2022/081777A1 |
A method of treating proteinuric kidney injury, comprising administering an effective isoLG scavenging amount of at least one compound of the present invention.
|
|
WO/2022/073115A1 |
Compounds of Formula I or II, methods of preparation and of use thereof. Formula I has a core aromatic group with substituents as follows: Formula (I) wherein G1 is -(CH2)nC(R1)(R2)OH, -(CH2)n-CHO, -(CH2)nC(O)NR1R2, -(CH2)nCH (R1)NR1R2, ...
|
|
WO/2022/069002A1 |
The invention relates to a compound, to a rubber mixture containing the compound, to a vehicle tire which has at least one component comprising the rubber mixture, to a method for producing the compound, and to the use of the compound as...
|
|
WO/2022/061193A1 |
Provided are vitamin D3 derivatives of formula (I), pharmaceutical compositions thereof, and pharmaceutical or medical uses thereof for treating metabolic disease, a liver disease, obesity, diabetes, cardiovascular disease, or cancer in ...
|
|
WO/2022/055781A1 |
There is disclosed a process for recovering monoethanolamine from an aqueous mother liquor solution comprising the steps of: (a) adding excess ammonia or alkali hydroxide and a solvent to the aqueous solution comprised of monoethanolamin...
|
|
WO/2022/052683A1 |
The present invention provides a method for preparing a water-soluble magnolol derivative and a honokiol derivative, methods for preparing intermediates of a water-soluble magnolol derivative and a honokiol derivative, and a related mono...
|
|
WO/2022/028557A1 |
A 18F-labeled biphenyl compound, an intermediate thereof, a preparation method therefor, a pharmaceutical composition thereof, and application thereof. The biphenyl compound has a significant suppression effect on PD-1 and/or PD-L1, can ...
|
|
WO/2022/030447A1 |
A fluorinated diamine represented by general formula [1A] or a salt thereof; a polyamide including a structural unit derived from the diamine or salt; and a cyclized polyamide. In general formula [1A], R1 represents, or the multiple moie...
|
|
WO/2022/020963A1 |
A method for the synthesis of specialized pro-resolving mediators, structural isomers thereof and analogs thereof is disclosed herein. The method comprises reacting a compound of the formula (I): (I) wherein R1 is alkyl(C≤12), cycloalk...
|
|
WO/2022/022388A1 |
Provided is a dezocine derivative crystal form A. The X-ray powder diffraction spectrum of the crystal form A, expressed by a diffraction angle of 2θ±0.2°, shows characteristic peaks at 8.894, 9.496, 10.974, 13.334, 15.338, 15.942, 17...
|
|
WO/2022/011792A1 |
The present invention provides a diquaternary ammonium salt intermediate preparation process, comprising: reacting a 1,3-Dichloro-2-propanol and a long carbon chain dimethylamine in acetone, producing the diquaternary ammonium salt inter...
|
|
WO/2022/009782A1 |
Polybenzoxazole having a structural unit represented by general formula [1]. In general formula [1], R1 is a tetravalent organic group represented by general formula [2], and R2 is a divalent organic group. In general formula [2]: the tw...
|
